HC Wainwright & Co. Maintains Buy on ORIC Pharmaceuticals, Lowers Price Target to $15
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Robert Burns has maintained a Buy rating on ORIC Pharmaceuticals (NASDAQ:ORIC) but reduced the price target from $16 to $15.

December 13, 2023 | 11:29 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
ORIC Pharmaceuticals' Buy rating is maintained by HC Wainwright & Co., but the price target is lowered from $16 to $15.
While the Buy rating reaffirms confidence in ORIC Pharmaceuticals' prospects, the reduction in price target could suggest a more conservative valuation or a response to recent developments. This mixed signal may lead to a neutral short-term impact on the stock price as the market digests the implications of the lowered target alongside the maintained positive rating.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100